AMRX Amneal Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NYSE: AMRX

Price (delayed)

$5.64

Market cap

$1.7B

P/E Ratio

80.57

Dividend/share

N/A

EPS

$0.07

Enterprise value

$4.33B

Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in ...

Highlights
AMRX's EPS has soared by 164% since the previous quarter and by 105% year-on-year
The company's net income has surged by 153% QoQ and by 105% YoY
AMRX's quick ratio is down by 10% from the previous quarter but it is up by 7% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.amneal.com
Peers: ONTX OPK

Key stats

What are the main financial stats of AMRX
Market
Shares outstanding
301.39M
Market cap
$1.7B
Enterprise value
$4.33B
Valuations
Price to earnings (P/E)
80.57
Price to book (P/B)
4.9
Price to sales (P/S)
0.41
EV/EBIT
28.65
EV/EBITDA
11.33
EV/Sales
2.11
Earnings
Revenue
$2.06B
EBIT
$151.26M
EBITDA
$382.53M
Free cash flow
$179.76M
Per share
EPS
$0.07
Free cash flow per share
$1.21
Book value per share
$1.15
Revenue per share
$13.81
TBVPS
$14.64
Balance sheet
Total assets
$4.02B
Total liabilities
$3.63B
Debt
$2.92B
Equity
$346.11M
Working capital
$890.61M
Liquidity
Debt to equity
8.43
Current ratio
2.32
Quick ratio
1.39
Net debt/EBITDA
6.89
Margins
EBITDA margin
18.6%
Gross margin
34.3%
Net margin
0.4%
Operating margin
6.6%
Efficiency
Return on assets
0.2%
Return on equity
2.9%
Return on invested capital
3.7%
Return on capital employed
4.5%
Return on sales
7.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMRX stock price

How has the Amneal Pharmaceuticals stock price performed over time
Intraday
-1.57%
1 week
0.36%
1 month
13.94%
1 year
11.9%
YTD
23.41%
QTD
5.62%

Financial performance

How have Amneal Pharmaceuticals's revenue and profit performed over time
Revenue
$2.06B
Gross profit
$704.72M
Operating income
$135.64M
Net income
$9.23M
Gross margin
34.3%
Net margin
0.4%
The company's net income has surged by 153% QoQ and by 105% YoY
AMRX's net margin has surged by 144% since the previous quarter and by 104% year-on-year
The company's operating income has surged by 71% QoQ
The operating margin has surged by 65% since the previous quarter

Growth

What is Amneal Pharmaceuticals's growth rate over time

Valuation

What is Amneal Pharmaceuticals stock price valuation
P/E
80.57
P/B
4.9
P/S
0.41
EV/EBIT
28.65
EV/EBITDA
11.33
EV/Sales
2.11
AMRX's EPS has soared by 164% since the previous quarter and by 105% year-on-year
Amneal Pharmaceuticals's equity has increased by 13% YoY and by 7% QoQ
The price to book (P/B) is 2.1% higher than the last 4 quarters average of 4.8
AMRX's revenue is up by 18% year-on-year and by 3.5% since the previous quarter
The price to sales (P/S) is 2.5% higher than the last 4 quarters average of 0.4

Efficiency

How efficient is Amneal Pharmaceuticals business performance
Amneal Pharmaceuticals's return on equity has surged by 152% QoQ and by 104% YoY
The company's return on assets has surged by 150% QoQ and by 104% YoY
AMRX's ROS is down by 50% year-on-year but it is up by 16% since the previous quarter
AMRX's ROIC is down by 41% YoY but it is up by 19% from the previous quarter

Dividends

What is AMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMRX.

Financial health

How did Amneal Pharmaceuticals financials performed over time
AMRX's total assets is 11% greater than its total liabilities
AMRX's quick ratio is down by 10% from the previous quarter but it is up by 7% YoY
The company's current ratio fell by 5% QoQ but it rose by 2.7% YoY
Amneal Pharmaceuticals's equity has increased by 13% YoY and by 7% QoQ
The company's debt to equity fell by 13% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.